SEC 13F Intelligence

Fairmount Funds Management LLC / AXSM

Fairmount Funds Management LLC’s Axsome Therapeutics Inc. Position

Does Fairmount Funds Management LLC own Axsome Therapeutics Inc. (AXSM)? Not currently — the last reported position was 815.2K shares worth $99M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$99M
Q3 2025
Shares
815.2K
% of Portfolio
+8.91%
Quarters Held
23
position exited

Position History AXSM

Reported value by quarter
Q1 ’20: $11MQ1 ’20Q2 ’20: $18MQ3 ’20: $16MQ4 ’20: $18MQ4 ’20Q1 ’21: $14MQ2 ’21: $21MQ3 ’21: $6MQ3 ’21Q4 ’21: $7MQ1 ’22: $39MQ2 ’22: $36MQ2 ’22Q3 ’22: $85MQ4 ’22: $155MQ1 ’23: $124MQ1 ’23Q2 ’23: $169MQ3 ’23: $164MQ4 ’23: $188MQ4 ’23Q1 ’24: $188MQ2 ’24: $190MQ3 ’24: $212MQ3 ’24Q4 ’24: $124MQ1 ’25: $95MQ2 ’25: $85MQ2 ’25Q3 ’25: $99Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025815.2K$99M+8.91%
Q2 2025815.2K$85M+11.02%
Q1 2025815.2K$95M+14.75%
Q4 20241.47M$124M+12.36%
Q3 20242.36M$212M+17.20%
Q2 20242.36M$190M+21.46%
Q1 20242.36M$188M+20.53%
Q4 20232.36M$188M+19.85%
Q3 20232.34M$164M+19.69%
Q2 20232.34M$169M+23.76%
Q1 20232.01M$124M+21.34%
Q4 20222.01M$155M+24.61%
Q3 20221.90M$85M+14.88%
Q2 2022942.6K$36M+8.26%
Q1 2022942.6K$39M+9.22%
Q4 2021187.6K$7M+2.34%
Q3 2021187.6K$6M+2.25%
Q2 2021312.6K$21M+8.67%
Q1 2021251.6K$14M+6.00%
Q4 2020220.1K$18M+6.41%
Q3 2020220.1K$16M+6.64%
Q2 2020216.1K$18M+7.93%
Q1 2020189.6K$11M+6.76%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Fairmount Funds Management LLC’s full portfolio or all institutional holders of AXSM.